icon-    folder.gif   Conference Reports for NATAP  
 
  26th Conference of the Asian Pacific
Association for the Study of the Liver
2017 APASL, Feb 15-19
Shanghai, China

Back grey_arrow_rt.gif
 
 
 
PROJECTED IMPACT OF ELBASVIR/GRAZOPREVIR IN TREATMENT-NÁVE AND TREATMENT-EXPERIENCED PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 AND CHRONIC KIDNEY DISEASE IN VIETNAM
 
 
  Reported by Jules Levin
APASL 2017 Feb 15-19 Shanghai, China
 
Chizoba Nwankwo, PhD;1 Elamin H. Elbasha, PhD;1 Thuy Thi Thu Nguyen, PhD, MBA;2 Nguyen Khac Luong Quang, MD, PhD;3 Shelby Corman, PharmD, MS, BCPS;4 1. Merck & Co., Inc., Kenilworth, NJ, USA 2. University of Medicine and Pharmacy, Ho Chi Minh city, Vietnam 3. Merck Sharp & Dohme, Ho Chi Minh city, Vietnam 4. Pharmerit International, Bethesda, M

0221171

"reduce lifetime cumulative incidence of decompensated cirrhosis -
 
....incidence of hepatocellular carcinoma
 
....reduced End-stage Liver Disease mortality
 
....extended life expectancy
 
.......projected higher average discounted quality-adjusted life years"
 
D, USA

0221172

1. Van K.N. et al Renal Society of Australasia Journal 2012;8(3):140-145; 2. DDD; 3. Roth D. et al Lancet 2015 Oct 17;386(10003):1537-45

0221173

0221174

0221175

0221176